Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Son, Sohee | - |
dc.contributor.author | Lim, Sung Mook | - |
dc.contributor.author | Chae, Su Young | - |
dc.contributor.author | Kim, Kwangmeyung | - |
dc.contributor.author | Park, Eun Ji | - |
dc.contributor.author | Lee, Kang Choon | - |
dc.contributor.author | Na, Dong Hee | - |
dc.date.accessioned | 2024-01-20T05:33:58Z | - |
dc.date.available | 2024-01-20T05:33:58Z | - |
dc.date.created | 2022-01-25 | - |
dc.date.issued | 2015-11 | - |
dc.identifier.issn | 0378-5173 | - |
dc.identifier.uri | https://pubs.kist.re.kr/handle/201004/124780 | - |
dc.description.abstract | Hydrophobically modified glycol chitosan (HGC) nanoparticles loaded with mono-lithocholic acid-conjugated exendin-4 at the Lys(27) residue (LAM1-Ex4) were prepared and characterized by particle size measurement, proteolytic stability, in vitro drug-release profile, and in vivo antidiabetic effects in a db/db diabetic mouse model. Compared with Ex-4-loaded HGC nanoparticles (Ex4/HGC NPs) prepared as a control, LAM1-Ex4-loaded HGC nanoparticles (LAM1-Ex4/HGC NPs) showed improved drug-loading efficiency, small particle size, enhanced resistance against proteolytic digestion, and an extended in vitro drug release profile. These findings may be attributable to the strong hydrophobic interaction between LAM1-Ex4 and the inner core of HGC. Furthermore, LAM1-Ex4/HGC NPs showed prolonged hypoglycemic efficacy in db/db mice, lasting 1 week after a single subcutaneous administration. The present study demonstrated that LAM1-Ex4/HGC NPs have considerable potential as a long-acting sustained-release antidiabetic system for type 2 diabetes. (C) 2015 Elsevier B.V. All rights reserved. | - |
dc.language | English | - |
dc.publisher | ELSEVIER | - |
dc.title | Mono-lithocholated exendin-4-loaded glycol chitosan nanoparticles with prolonged antidiabetic effects | - |
dc.type | Article | - |
dc.identifier.doi | 10.1016/j.ijpharm.2015.08.084 | - |
dc.description.journalClass | 1 | - |
dc.identifier.bibliographicCitation | INTERNATIONAL JOURNAL OF PHARMACEUTICS, v.495, no.1, pp.81 - 86 | - |
dc.citation.title | INTERNATIONAL JOURNAL OF PHARMACEUTICS | - |
dc.citation.volume | 495 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 81 | - |
dc.citation.endPage | 86 | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.identifier.wosid | 000362970000010 | - |
dc.identifier.scopusid | 2-s2.0-84940727466 | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.type.docType | Article | - |
dc.subject.keywordPlus | PEGYLATED EXENDIN-4 | - |
dc.subject.keywordPlus | TYPE-2 | - |
dc.subject.keywordPlus | EXENATIDE | - |
dc.subject.keywordPlus | STABILITY | - |
dc.subject.keywordPlus | DELIVERY | - |
dc.subject.keywordPlus | RECEPTOR | - |
dc.subject.keywordPlus | RELEASE | - |
dc.subject.keywordPlus | WEIGHT | - |
dc.subject.keywordPlus | ANALOG | - |
dc.subject.keywordAuthor | Exendin-4 | - |
dc.subject.keywordAuthor | Glycol chitosan | - |
dc.subject.keywordAuthor | Nanoparticles | - |
dc.subject.keywordAuthor | Lithocholic acid | - |
dc.subject.keywordAuthor | Antidiabetic effects | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.